Literature DB >> 28339167

If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia.

E Berntorp1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28339167     DOI： 10.1111/jth.13682

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  9 in total

1.  Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.

Authors:  João A Abrantes; Siv Jönsson; Mats O Karlsson; Elisabet I Nielsen
Journal:  Br J Clin Pharmacol       Date:  2019-04-29       Impact factor: 4.335

Review 2.  Hemophilia Care in the Pediatric Age.

Authors:  Marta Bertamino; Francesca Riccardi; Laura Banov; Johanna Svahn; Angelo Claudio Molinari
Journal:  J Clin Med       Date:  2017-05-19       Impact factor: 4.241

Review 3.  The role of orthopaedic surgery in haemophilia: current rationale, indications and results.

Authors:  E Carlos Rodríguez-Merchán
Journal:  EFORT Open Rev       Date:  2019-05-10

4.  Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.

Authors:  Alexander Solms; Alfonso Iorio; Maurice J Ahsman; Peter Vis; Anita Shah; Erik Berntorp; Dirk Garmann
Journal:  Clin Pharmacokinet       Date:  2020-05       Impact factor: 6.447

5.  Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program.

Authors:  Samuel Sarmiento Doncel; Gina Alejandra Diaz Mosquera; Javier Mauricio Cortes; Nelson Ramirez Plazas; Francisco Javier Meza; Carol Agudelo Rico
Journal:  Hematol Rep       Date:  2021-11-26

6.  Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.

Authors:  Laura H Bukkems; Lars L F G Valke; Wideke Barteling; Britta A P Laros-van Gorkom; Nicole M A Blijlevens; Marjon H Cnossen; Waander L van Heerde; Saskia E M Schols; Ron A A Mathôt
Journal:  Br J Clin Pharmacol       Date:  2022-01-15       Impact factor: 3.716

7.  Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.

Authors:  João A Abrantes; Alexander Solms; Dirk Garmann; Elisabet I Nielsen; Siv Jönsson; Mats O Karlsson
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

8.  Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.

Authors:  João A Abrantes; Alexander Solms; Dirk Garmann; Elisabet I Nielsen; Siv Jönsson; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-30

Review 9.  Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.

Authors:  Cedric Hermans; Gerry Dolan
Journal:  Ther Adv Hematol       Date:  2020-10-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.